Literature DB >> 25074740

Residual perfusion defects in patients with pulmonary embolism are related to impaired fibrinolytic capacity.

Donatella Lami1, Anna Paola Cellai2, Emilia Antonucci3, Claudia Fiorillo4, Matteo Becatti4, Elisa Grifoni3, Caterina Cenci3, Rossella Marcucci3, Lucia Mannini2, Massimo Miniati3, Rosanna Abbate3, Domenico Prisco3.   

Abstract

BACKGROUND: Few studies investigated the relationship between fibrinolysis abnormalities and residual pulmonary perfusion defects after acute pulmonary embolism (PE).
OBJECTIVE: To assess the fibrinolytic profile in patients with prior PE in relation to the extent of scintigraphically detectable residual perfusion abnormalities. PATIENTS AND METHODS: We studied 71 consecutive patients with a prior episode of PE, who were examined after one year of the incident embolic event, and at least one month after anticoagulation withdrawal. They underwent lung scintigraphy to assess the recovery of pulmonary perfusion, echocardiography and chest radiography to look for signs of pulmonary hypertension. Clot formation and lysis were evaluated by two turbidimetric methods: Clot and Lysis Assay and Clot Lysis Time. We also measured the in vitro plasmin-mediated lysis of fibrin from purified fibrinogen, and the circulating levels of fibrinolytic inhibitors. The sample was split in two categories based on the extent of residual perfusion defects: <10% (n=53), ≥ 10% (n=18).
RESULTS: Patients with perfusion defects >10% had significantly longer lysis time (p<0.05), and higher levels of plasminogen activator inhibitor-1 (p<0.01) than those with perfusion defects <10%. The time interval between symptoms onset and PE diagnosis (time-to-diagnosis) was significantly longer in patients with perfusion defects >10% than in the others (p=0.005). In multivariate logistic regression, both lysis time and time-to-diagnosis were independently associated with perfusion defects >10% (p<0.001). None of the sampled patients had echocardiographic or radiologic signs of pulmonary hypertension.
CONCLUSION: Prolonged time-to-diagnosis and fibrinolysis imbalance are independent predictors of incomplete perfusion recovery after acute PE.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clot lysis time; Fibrinolysis; Pulmonary embolism; Residual perfusion defects

Mesh:

Substances:

Year:  2014        PMID: 25074740     DOI: 10.1016/j.thromres.2014.07.013

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence.

Authors:  Anetta Undas
Journal:  Biomed Res Int       Date:  2017-06-27       Impact factor: 3.411

2.  Identifying the heterogeneity of COPD by V/P SPECT: a new tool for improving the diagnosis of parenchymal defects and grading the severity of small airways disease.

Authors:  M Bajc; Y Chen; J Wang; X Y Li; W M Shen; C Z Wang; H Huang; A Lindqvist; X Y He
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-05-26

3.  Faster fibrin clot degradation characterizes patients with central pulmonary embolism at a low risk of recurrent peripheral embolism.

Authors:  Robert W Kupis; Sarah Goldman-Mazur; Maciej Polak; Michał Ząbczyk; Anetta Undas
Journal:  Sci Rep       Date:  2019-01-11       Impact factor: 4.379

4.  Fibrinogen and the prediction of residual obstruction manifested after pulmonary embolism treatment.

Authors:  Benjamin Planquette; Olivier Sanchez; James J Marsh; Peter G Chiles; Joseph Emmerich; Grégoire Le Gal; Guy Meyer; Tanya Wolfson; Anthony C Gamst; Roger E Moore; Gabriel B Gugiu; Timothy A Morris
Journal:  Eur Respir J       Date:  2018-11-15       Impact factor: 33.795

5.  A multifaceted investigation into molecular associations of chronic thromboembolic pulmonary hypertension pathogenesis.

Authors:  Stephen J Halliday; Daniel T Matthews; Megha H Talati; Eric D Austin; Yan R Su; Tarek S Absi; Niki L Fortune; David Gailani; Anton Matafonov; James D West; Anna R Hemnes
Journal:  JRSM Cardiovasc Dis       Date:  2020-02-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.